Navega Therapeutics

[On Demand]

Navega Therapeutics is harnessing the precision of CRISPR and zinc finger epigenome regulation to enable next-generation gene therapies for neurological and ophthalmologic diseases. Our lead candidates are radically different approaches to treat chronic pain and retinitis pigmentosa.


Navega Therapeutics is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Gene Therapies for Chronic Pain and RP
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Navega Therapeutics